MedTrace Logo

A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

NCT07421232 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2026-02-19

No results posted yet for this study

Summary

The purpose of this study is to compare the effectiveness, safety of SYH2053 in Participants with primary hypercholesterolemia or mixed dyslipidemia.

A total of 156 Participants were actually enrolled

Conditions

  • Hypercholesterolemia and Mixed Hyperlipidemia

Interventions

DRUG

SYH2053/placebo injection

Participants receive SYH2053/placebo injection by subcutaneous administration.

DRUG

Inclisiran (Leqvio®) 300mg

Participants receive Leqvio® injection by subcutaneous administration.

Sponsors & Collaborators

  • CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-03
Primary Completion
2025-08-30
Completion
2026-02-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07421232 on ClinicalTrials.gov